Invasive Fungal Infections Market Poised for Robust Growth by 2036 as Novel Broad-Spectrum Antifungals Advance Through Pipeline
Key Insights
The US invasive fungal infections (search) market was valued at nearly USD 390 million in 2025 and is projected to expand significantly through 2036, driven by rising immunocompromised populations and novel antifungal launches.
Approximately 112,000 incident cases of invasive fungal infections (search) occurred in the United States in 2025, with invasive candidiasis (search) and invasive aspergillosis (search) accounting for nearly 50% of the total disease burden.
Nearly 90% of patients eventually develop resistance to first-line antifungal therapy, while around 30% develop resistance to second-line agents, underscoring the urgent need for drugs with novel mechanisms of action.
The invasive fungal infections (search) (IFIs) treatment landscape is undergoing a significant transformation, with the US market valued at nearly USD 390 million in 2025 and projected to expand substantially through 2036, according to a new report from DelveInsight. This growth is fueled by the rising incidence of opportunistic fungal infections in immunocompromised patients, increasing antifungal resistance, and the anticipated approval of several first-in-class broad-spectrum antifungal agents.
The report, titled "DelveInsight's Invasive Fungal Infections (search) (IFIs) Market Insights, Epidemiology, and Market Forecast – 2036," provides a comprehensive analysis across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. It estimates that approximately 112,000 incident cases of IFIs occurred in the United States in 2025, with the patient population expected to increase steadily as the number of immunocompromised individuals and critically ill patients continues to grow.
Disease Burden and Treatment Gaps
Invasive candidiasis (search) and invasive aspergillosis (search) together account for nearly 50% of the total IFI burden, making them the leading contributors to disease prevalence and antifungal drug utilization across major markets. Despite the availability of antifungal agents such as azoles, echinocandins, polyenes, and flucytosine, significant clinical challenges persist.
The report highlights a substantial treatment gap: approximately 70% of diagnosed patients currently receive systemic antifungal therapy, leaving a considerable proportion of patients without adequate treatment. More concerning, nearly 90% of patients eventually develop resistance to first-line antifungal therapy, while around 30% subsequently develop resistance to second-line agents. The emergence of multidrug-resistant fungal pathogens, including Candida auris, azole-resistant Aspergillus, and resistant Candida species, has become a major clinical challenge driving demand for innovative therapies.
Pipeline Innovation and Novel Mechanisms
The IFIs pipeline is rapidly evolving, with several promising therapies in mid- and late-stage clinical development. Among the most anticipated candidates is Fosmanogepix, a first-in-class broad-spectrum antifungal agent being developed by Basilea Pharmaceutica. Fosmanogepix targets the fungal Gwt1 protein (search), a novel mechanism essential for fungal cell wall integrity, and has demonstrated potent activity against Candida, Candida auris, Aspergillus, Fusarium, Scedosporium, endemic fungi, and several rare molds. In July 2025, Basilea received USD 39 million under its BARDA agreement to continue advancing Fosmanogepix, with ongoing Phase III clinical studies evaluating the therapy for candidemia, invasive candidiasis (search), and invasive mold infections.
Olorofim, developed by Shionogi (search) and F2G, represents another first-in-class approach as a dihydroorotate dehydrogenase (search) (DHODH) inhibitor with potent activity against difficult-to-treat molds, including invasive aspergillosis (search). SCY-247, a second-generation triterpenoid antifungal from SCYNEXIS, has demonstrated broad-spectrum activity, excellent tissue penetration, and promising efficacy against Candida auris and other resistant pathogens. In January 2026, the US FDA granted SCY-247 both Qualified Infectious Disease Product (QIDP) designation and Fast Track Designation, and the company presented new preclinical data at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) highlighting its potent activity against resistant fungal pathogens.
MAT2203, from Matinas BioPharma (search), is being developed as an innovative oral lipid nanocrystal formulation designed to improve amphotericin B delivery while reducing systemic toxicity, addressing a longstanding limitation of this potent but toxic antifungal class.
Market Dynamics and Competitive Landscape
The United States accounted for the largest IFIs treatment market in 2025 and is expected to maintain its leadership position throughout the forecast period, supported by higher diagnosis rates, greater adoption of innovative antifungal therapies, favorable reimbursement policies, and increased awareness among healthcare professionals.
Key companies shaping the competitive landscape include Basilea Pharmaceutica, F2G Biotech GmbH, Shionogi (search), SCYNEXIS, Pulmocide, Matinas BioPharma (search), Cidara Therapeutics, and Pfizer. Basilea's CRESEMBA continues to demonstrate strong commercial performance, with milestone payments triggered through its commercialization partnership with Pfizer following robust sales growth across the Asia-Pacific region.
The growing number of innovative therapies targeting novel fungal pathways, combined with increasing investment in infectious disease research, is expected to significantly reshape the IFIs treatment market over the next decade. Advances in molecular diagnostics, fungal biomarkers, PCR-based assays, and next-generation sequencing are further enabling earlier diagnosis and timely targeted antifungal therapy, improving clinical outcomes while reducing mortality and healthcare costs.